<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04077359</url>
  </required_header>
  <id_info>
    <org_study_id>2019/395</org_study_id>
    <nct_id>NCT04077359</nct_id>
  </id_info>
  <brief_title>Prospective Trial for Examining Hematuria Using Computed Tomography</brief_title>
  <acronym>PROTEHCT</acronym>
  <official_title>Prospective Trial for Examining Hematuria Using Computed Tomography</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oslo University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to evaluate whether one-phase nephrographic CT (experimental) is
      sufficient to detect urinary tract cancer in patients with hematuria compared to the
      traditional four-phase CT (control).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Responsible centers Oslo University Hospital, Aker. Division of Radiology and Nuclear
      medicine.

      Study type: Prospective clinical trial

      Study design: One sample, non-inferiority study with a 7.5% non-inferiority limit.

      Investigational product: One phase nephrographic CT (experimental arm) vs. Four-phase CT
      (control arm)

      Objective:The primary objective is to evaluate whether one-phase nephrographic CT
      (experimental) is sufficient to detect urinary tract cancer in patients with hematuria
      compared to the traditional four-phase CT (control).

      Primary endpoints: The difference in false negative rates in the experimental- and control
      arm. McNemara is used for statistical analyses.

      there will also be a secondary reading in order to asses interobserver variability for both
      the experimental and the control arm

      Sample size:

      â€¢ 250 patients
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 15, 2019</start_date>
  <completion_date type="Anticipated">September 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>One sample, non-inferiority study with a 7.5% non-inferiority limit.</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Investigator)</masking>
    <masking_description>one investigator evaluates the experimental arm a second investigator evaluates the control arm without knowledge of the other</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>false negative rates</measure>
    <time_frame>all examinations are evaluated immediately after the CT examination</time_frame>
    <description>the rate of false negatives in the experimental arm will not exceed the the rate of false negatives found in the control-arm defined by the non-inferiority limit of 7.5%</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>cancer detection rates</measure>
    <time_frame>all examinations are evaluated immediately after the CT examination</time_frame>
    <description>cancer detection rates in the two arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the curve (AUC)</measure>
    <time_frame>all examinations are evaluated immediately after the CT examination</time_frame>
    <description>the difference in AUC of the two arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>predictive values</measure>
    <time_frame>all examinations are evaluated immediately after the CT examination</time_frame>
    <description>The difference in the predictive values of the two arms</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Urothelial Carcinoma</condition>
  <condition>Renal Cell Carcinoma</condition>
  <condition>Renal Cyst</condition>
  <condition>Renal Stone</condition>
  <arm_group>
    <arm_group_label>nephrographic phase CT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>the nephrographic phase will be evaluated alone by a radiologist blinded to the remaining series</description>
  </arm_group>
  <arm_group>
    <arm_group_label>gold standard</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>all series (unenhanced, corticomedullary, nephrographic and excretory phase) will be evaluated by a radiologist not involved in the experimental arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>CT</intervention_name>
    <description>the CT consist of four phases; non-enhanced, corticomedullary, nephrographic and excretory phase.</description>
    <arm_group_label>gold standard</arm_group_label>
    <arm_group_label>nephrographic phase CT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  One or more occasion with macroscopic hematuria without signs of urinary tract
             infection

          -  &gt;18 years old

        Exclusion Criteria:

          -  Previous history of cancer in the urinary tract

          -  Known staghorn calculi

          -  Previous iodine contrast medium allergy reaction

          -  For any reason, do not wish to participate in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Erik Rud</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oslo University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Erik Rud, MD, PhD</last_name>
    <phone>+47 93445684</phone>
    <email>erik.rud@ous-hf.no</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kristina Flor, MD</last_name>
    <email>kriflo@ous-hf.no</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Oslo University Hospital</name>
      <address>
        <city>Oslo</city>
        <zip>0524</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erik Rud, MD, PhD</last_name>
      <phone>+4793445684</phone>
      <email>erik.rud@ous-hf.no</email>
    </contact>
    <contact_backup>
      <last_name>Kristina Flor, MD</last_name>
      <email>kriflo@ous-hf.no</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>August 30, 2019</study_first_submitted>
  <study_first_submitted_qc>August 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 4, 2019</study_first_posted>
  <last_update_submitted>September 27, 2019</last_update_submitted>
  <last_update_submitted_qc>September 27, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oslo University Hospital</investigator_affiliation>
    <investigator_full_name>Erik Rud</investigator_full_name>
    <investigator_title>Consulting radiologist, PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
    <mesh_term>Carcinoma, Transitional Cell</mesh_term>
    <mesh_term>Hematuria</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

